AAAAAA

   
Results: 1-9 |
Results: 9
EVALUATION OF THE SAFETY AND PHARMACOKINETIC PROFILE OF A NEW, PASTEURIZED, HUMAN TETANUS IMMUNOGLOBULIN ADMINISTERED AS SHAM, POSTEXPOSUREPROPHYLAXIS OF TETANUS
Authors: FORRAT R DUMAS R SEIBERLING M MERZ M LUTSCH C LANG J
Citation: R. Forrat et al., EVALUATION OF THE SAFETY AND PHARMACOKINETIC PROFILE OF A NEW, PASTEURIZED, HUMAN TETANUS IMMUNOGLOBULIN ADMINISTERED AS SHAM, POSTEXPOSUREPROPHYLAXIS OF TETANUS, Antimicrobial agents and chemotherapy, 42(2), 1998, pp. 298-305
PHARMACOKINETICS AND DOSE PROPORTIONALITY OF SP W-4853, THE MAIN METABOLITE OF SP/W-5186 A NEW ORGANIC NITRATE/
Authors: BONN R BOKENS H HAMMES W TRENK D SEIBERLING M JAHNCHEN E
Citation: R. Bonn et al., PHARMACOKINETICS AND DOSE PROPORTIONALITY OF SP W-4853, THE MAIN METABOLITE OF SP/W-5186 A NEW ORGANIC NITRATE/, Naunyn-Schmiedeberg's archives of pharmacology, 357(4), 1998, pp. 627-627
PHARMACOKINETICS AND BIOAVAILABILITY OF MONTELUKAST SODIUM (MK-0476) IN HEALTHY-YOUNG AND ELDERLY VOLUNTEERS
Authors: ZHAO JJ ROGERS JD HOLLAND SD LARSON P AMIN RD HAESEN R FREEMAN A SEIBERLING M MERZ M CHENG HY
Citation: Jj. Zhao et al., PHARMACOKINETICS AND BIOAVAILABILITY OF MONTELUKAST SODIUM (MK-0476) IN HEALTHY-YOUNG AND ELDERLY VOLUNTEERS, Biopharmaceutics & drug disposition, 18(9), 1997, pp. 769-777
ELEVATION OF LIVER-ENZYMES IN MULTIPLE-DOSE TRIALS DURING PLACEBO-TREATMENT - ARE THEY PREDICTABLE
Authors: MERZ M SEIBERLING M HOXTER G HOLTING ML WORTHA HP
Citation: M. Merz et al., ELEVATION OF LIVER-ENZYMES IN MULTIPLE-DOSE TRIALS DURING PLACEBO-TREATMENT - ARE THEY PREDICTABLE, Journal of clinical pharmacology, 37(9), 1997, pp. 791-798
COMPARATIVE INVESTIGATION OF THE RELATIVE BIOAVAILABILITY AND PHARMACOKINETICS OF ESTRONE AFTER ORAL-ADMINISTRATION OF ESTERIFIED ESTROGENSAS SUGAR-COATED TABLETS FORMULATION AND AS ORAL SUSPENSION
Authors: DEGEN J WOLKE E SEIBERLING M THOMANN P VOLTERERHARDT H
Citation: J. Degen et al., COMPARATIVE INVESTIGATION OF THE RELATIVE BIOAVAILABILITY AND PHARMACOKINETICS OF ESTRONE AFTER ORAL-ADMINISTRATION OF ESTERIFIED ESTROGENSAS SUGAR-COATED TABLETS FORMULATION AND AS ORAL SUSPENSION, Arzneimittel-Forschung, 47(2), 1997, pp. 208-212
LACK OF SYSTEMIC ACTIVITY WITH INTRANASAL MOMETASONE FUROATE
Authors: BRANNAN MD SEIBERLING M CUTLER DL CUSS FM AFFRIME MB
Citation: Md. Brannan et al., LACK OF SYSTEMIC ACTIVITY WITH INTRANASAL MOMETASONE FUROATE, Journal of allergy and clinical immunology, 97(1), 1996, pp. 62-62
TOLERABILITY, SAFETY AND PHARMACOKINETICS OF SINGLE-DOSE AND MULTIPLEDOSING OF THE SELECTIVE D1 ANTAGONIST NNC-01-0687 IN HEALTHY-SUBJECTS
Authors: SKRUMSAGER BK CHRISTENSEN JV SNEL S SEIBERLING M
Citation: Bk. Skrumsager et al., TOLERABILITY, SAFETY AND PHARMACOKINETICS OF SINGLE-DOSE AND MULTIPLEDOSING OF THE SELECTIVE D1 ANTAGONIST NNC-01-0687 IN HEALTHY-SUBJECTS, Psychopharmacology, 121(3), 1995, pp. 294-299
SINGLE-DOSE INTERACTION STUDY OF DIPRAFENONE HCL AND PROPRANOLOL HCL IN HEALTHY-VOLUNTEERS
Authors: HINDERLING PH TENDOLKAR A DEE CM BARR WH SEIBERLING M DUERR H
Citation: Ph. Hinderling et al., SINGLE-DOSE INTERACTION STUDY OF DIPRAFENONE HCL AND PROPRANOLOL HCL IN HEALTHY-VOLUNTEERS, Journal of clinical pharmacology, 35(7), 1995, pp. 721-729
EVALUATION OF THE RELATIVE BIOAVAILABILIT Y AND THE PHARMACOKINETICS OF MYRTOL STANDARDIZED
Authors: ZIMMERMANN T SEIBERLING M THOMANN P KARABELNIK D
Citation: T. Zimmermann et al., EVALUATION OF THE RELATIVE BIOAVAILABILIT Y AND THE PHARMACOKINETICS OF MYRTOL STANDARDIZED, Arzneimittel-Forschung, 45-2(11), 1995, pp. 1198-1201
Risultati: 1-9 |